BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Roviello G, Petrioli R, Rosellini P, Multari AG, Conca R, Paganini G, Chiriacò G, Aieta M. The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer. Invest New Drugs 2019;37:524-30. [DOI: 10.1007/s10637-019-00725-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Chu Y, Xiao Z, Jing N, Yan W, Wang S, Ma B, Zhang J, Li Y. Arborinine, a potential LSD1 inhibitor, inhibits epithelial-mesenchymal transition of SGC-7901 cells and adriamycin-resistant gastric cancer SGC-7901/ADR cells. Invest New Drugs 2021;39:627-35. [PMID: 33215324 DOI: 10.1007/s10637-020-01016-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]